Login to Your Account

Clinic Roundup

Thursday, June 28, 2012
• Derma Sciences Inc., of Princeton, N.J., said results of its Phase II trial testing DSC127 in patients with diabetic foot ulcers will be published in the July 2012 issue of Wound Repair and Regeneration, with data showing preliminary evidence that the drug, a clinical formulation of NorLeu3-A(1,7), is safe and effective in accelerating the healing of diabetic foot ulcers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription